SL V30
Alternative Names: SL-V30Latest Information Update: 28 Aug 2022
At a glance
- Originator SL VAXiGEN
- Class DNA vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Hepatitis-B in South Korea (Parenteral)
- 01 Jul 2018 Preclinical trials in Hepatitis B in South Korea (unspecified route) (SL-VaxiGen pipeline, July 2018)